Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

Noam Barda; Michal Canetti; Mayan Gilboa; Victoria Indenboim; Keren Asraf; Yael Weiss-Ottolenghi; Sharon Amit; Daniel Zibly; Ram Doolman; Ella Mendelson; Dror Harats; Laurence S. Freedman; Yitshak Kreiss; Yaniv Lustig; Gili Regev-Yochay

doi:10.2807/1560-7917.ES.2022.27.39.2200701

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

Noam Barda, Michal Canetti, Mayan Gilboa, Victoria Indenboim, Keren Asraf, Yael Weiss-Ottolenghi, Sharon Amit, Daniel Zibly, Ram Doolman, Ella Mendelson, Dror Harats, Laurence S. Freedman, Yitshak Kreiss, Yaniv Lustig, Gili Regev-Yochay

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98- 1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.

Original language	English
Article number	2200701
Journal	Eurosurveillance
Volume	27
Issue number	39
DOIs	https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200701
State	Published - Sep 2022
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2022 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

Funding

GRY reports institutional grant funding of studies not related to the current study from Pfizer, consulting/honoraria from Teva, MSD, Astrazeneca, Pfizer and Moderna. NB and YL report institutional grants from Pfizer. All other authors report no conflicts of interest.

Funders	Funder number
Pfizer

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2807/1560-7917.ES.2022.27.39.2200701

Cite this

Barda, N., Canetti, M., Gilboa, M., Indenboim, V., Asraf, K., Weiss-Ottolenghi, Y., Amit, S., Zibly, D., Doolman, R., Mendelson, E., Harats, D., Freedman, L. S., Kreiss, Y., Lustig, Y., & Regev-Yochay, G. (2022). Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022. Eurosurveillance, 27(39), Article 2200701. https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200701

@article{ae7f315205d14ebaad13b326e88b04bb,

title = "Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022",

abstract = "We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98- 1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.",

author = "Noam Barda and Michal Canetti and Mayan Gilboa and Victoria Indenboim and Keren Asraf and Yael Weiss-Ottolenghi and Sharon Amit and Daniel Zibly and Ram Doolman and Ella Mendelson and Dror Harats and Freedman, {Laurence S.} and Yitshak Kreiss and Yaniv Lustig and Gili Regev-Yochay",

year = "2022",

month = sep,

doi = "10.2807/1560-7917.ES.2022.27.39.2200701",

language = "אנגלית",

volume = "27",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control (ECDC)",

number = "39",

}

Barda, N, Canetti, M, Gilboa, M, Indenboim, V, Asraf, K, Weiss-Ottolenghi, Y, Amit, S, Zibly, D, Doolman, R, Mendelson, E, Harats, D, Freedman, LS, Kreiss, Y, Lustig, Y & Regev-Yochay, G 2022, 'Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022', Eurosurveillance, vol. 27, no. 39, 2200701. https://doi.org/10.2807/1560-7917.ES.2022.27.39.2200701

TY - JOUR

T1 - Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

AU - Barda, Noam

AU - Canetti, Michal

AU - Gilboa, Mayan

AU - Indenboim, Victoria

AU - Asraf, Keren

AU - Weiss-Ottolenghi, Yael

AU - Amit, Sharon

AU - Zibly, Daniel

AU - Doolman, Ram

AU - Mendelson, Ella

AU - Harats, Dror

AU - Freedman, Laurence S.

AU - Kreiss, Yitshak

AU - Lustig, Yaniv

AU - Regev-Yochay, Gili

PY - 2022/9

Y1 - 2022/9

N2 - We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98- 1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.

AB - We assess the immunogenicity and efficacy of Spikevax and Comirnaty as fourth dose COVID-19 vaccines. Six months post-fourth-dose, IgG levels were higher than pre-fourth dose at 1.58-fold (95% CI: 1.27-1.97) in Spikevax and 1.16-fold (95% CI: 0.98- 1.37) in Comirnaty vaccinees. Nearly 60% (159/274) of vaccinees contracted SARS-CoV-2. Infection hazard ratios (HRs) for Spikevax (0.82; 95% CI: 0.62-1.09) and Comirnaty (0.86; 95% CI: 0.65-1.13) vaccinees were similar, as were substantial-disease HRs, i.e. 0.28 (95% CI: 0.13-0.62) and 0.51 (95% CI: 0.27-0.96), respectively.

UR - http://www.scopus.com/inward/record.url?scp=85138961736&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES.2022.27.39.2200701

DO - 10.2807/1560-7917.ES.2022.27.39.2200701

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 36177870

AN - SCOPUS:85138961736

SN - 1025-496X

VL - 27

JO - Eurosurveillance

JF - Eurosurveillance

IS - 39

M1 - 2200701

ER -

Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this